Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

905
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
905
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

134
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
134

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PregMedNet: Multifaceted maternal medication impacts on neonatal complications.

Nature communications·2026
Same author

Development of Longitudinal, Linked Maternal-Infant Cohorts using the Epic Cosmos Electronic Health Record Dataset.

medRxiv : the preprint server for health sciences·2026
Same author

Continuing Glucagon-Like Peptide-1 Receptor Agonists Into the First Trimester of Pregnancy and Pregnancy Outcomes : A Target Trial Emulation Study Using Claims Information.

Annals of internal medicine·2026
Same author

The effect of a multifaceted intervention on post-operative opioid use after orthopedic and spine surgery: Results of a before-after pilot study.

Journal of opioid management·2026
Same author

Letter to the Editor regarding "Perioperative outcomes of maternal fetal medicine specialist as primary surgeon for placenta accreta spectrum hysterectomies".

American journal of obstetrics & gynecology MFM·2026
Same author

Prenatal exposure to buprenorphine or methadone and adverse neurodevelopmental outcomes: population based cohort study.

BMJ (Clinical research ed.)·2026

Related Experiment Video

Updated: Apr 10, 2026

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development
07:56

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development

Published on: January 26, 2018

16.5K

Second-Line Uterotonics for Uterine Atony: A Randomized Controlled Trial.

Naida M Cole1, Jimin J Kim, Mario I Lumbreras-Marquez

  • 1Department of Anesthesia and Critical Care, University of Chicago Medicine, Chicago, Illinois; the Department of Anesthesiology, Perioperative and Pain Medicine and the Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts; the Epidemiology and Public Health Division, Universidad Panamericana School of Medicine, Mexico City, Mexico; the Department of Anesthesiology, Pain Management and Perioperative Medicine, Henry Ford Hospital, Detroit, Michigan; the Department of Anesthesiology, Perioperative Medicine and Pain Management, University of Miami Miller School of Medicine, Miami, Florida; and the Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, California.

Obstetrics and Gynecology
|September 26, 2024
PubMed
Summary

Methylergonovine maleate and carboprost tromethamine showed similar efficacy for treating refractory uterine atony after cesarean delivery. Both uterotonics are acceptable second-line treatments when oxytocin is ineffective.

More Related Videos

Introduction of Intracapsular Rotary-cut Procedures IRCP: A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation
05:46

Introduction of Intracapsular Rotary-cut Procedures IRCP: A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation

Published on: January 17, 2019

9.9K
Ex Vivo Method for Assessing the Mouse Reproductive Tract Spontaneous Motility and a MATLAB-based Uterus Motion Tracking Algorithm for Data Analysis
06:22

Ex Vivo Method for Assessing the Mouse Reproductive Tract Spontaneous Motility and a MATLAB-based Uterus Motion Tracking Algorithm for Data Analysis

Published on: September 1, 2019

8.9K

Related Experiment Videos

Last Updated: Apr 10, 2026

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development
07:56

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development

Published on: January 26, 2018

16.5K
Introduction of Intracapsular Rotary-cut Procedures IRCP: A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation
05:46

Introduction of Intracapsular Rotary-cut Procedures IRCP: A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation

Published on: January 17, 2019

9.9K
Ex Vivo Method for Assessing the Mouse Reproductive Tract Spontaneous Motility and a MATLAB-based Uterus Motion Tracking Algorithm for Data Analysis
06:22

Ex Vivo Method for Assessing the Mouse Reproductive Tract Spontaneous Motility and a MATLAB-based Uterus Motion Tracking Algorithm for Data Analysis

Published on: September 1, 2019

8.9K

Area of Science:

  • Obstetrics and Gynecology
  • Pharmacology
  • Clinical Trials

Background:

  • Uterine atony is a leading cause of postpartum hemorrhage.
  • Second-line uterotonics are crucial for managing refractory uterine atony.
  • Methylergonovine maleate and carboprost tromethamine are commonly used agents.

Purpose of the Study:

  • To compare the efficacy of methylergonovine maleate and carboprost tromethamine as second-line uterotonics.
  • To evaluate their effectiveness in patients undergoing cesarean delivery with oxytocin-refractory uterine atony.

Main Methods:

  • A double-blind, randomized trial was conducted at two academic perinatal centers.
  • 100 patients with refractory uterine atony received either methylergonovine or carboprost.
  • Uterine tone was assessed using a 0-10 numeric rating scale 10 minutes post-administration.

Main Results:

  • No significant difference in mean uterine tone scores was observed between methylergonovine (7.3±1.7) and carboprost (7.6±2.1) at 10 minutes (P =.76).
  • Rates of additional uterotonic use (30.0% vs 34.0%) and quantitative blood loss (756 mL vs 708 mL) were similar between groups.
  • No differences were detected in other interventions for uterine atony or hemorrhage.

Conclusions:

  • Methylergonovine maleate and carboprost tromethamine demonstrate comparable efficacy in improving uterine tone for refractory uterine atony.
  • Both agents are acceptable treatment options when initial oxytocin therapy fails.
  • Further research may explore patient-specific factors influencing treatment response.